Pretax income is the income that a company earns before paying income taxes. Kintara Therapeutics's pretax income for the
three
months ended in Dec. 2023 was $-1.02 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-10.58 Mil.
Kintara Therapeutics's pretax margin was %.
Kintara Therapeutics Pre-Tax Income Historical Data
The historical data trend for Kintara Therapeutics's Pre-Tax Income can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Kintara Therapeutics's Pre-Tax Income
For the Biotechnology subindustry, Kintara Therapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintara Therapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintara Therapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Kintara Therapeutics's Pre-Tax Income falls into.
Kintara Therapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Kintara Therapeutics's Pretax Income for the fiscal year that ended in Jun. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintara Therapeutics (NAS:KTRA) Pre-Tax Income Explanation
Kintara Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintara Therapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Kintara Therapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Kintara Therapeutics (Kintara Therapeutics) Business Description
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KTRA has been successfully added to your 